COPD (Chronic Obstructive Pulmonary Disease) affects 210 million people worldwide, with 3 million deaths a year. Menarini Group supported a survey aimed at studying the communication between patients and doctors in relation to COPD and the survey were presented at the 2017 European Respiratory Society Congress in Milan. Among other findings, the study showed that 9 out of 10 patients with COPD do not inform their doctors about their real condition and the consequence of this communication gap are reflected in the patients' state of health.
With an extensive brands portfolio, Menarini Asia-Pacific markets a wide range of branded pharmaceutical, biotechnology, medical device and consumer health brands across key markets in Asia-Pacific. Building on our strengths in Dermatology, Select Specialty Care, Consumer Health, where we have experienced impressive success in these therapeutic fields, Menarini Asia-Pacific is now extending its offerings to include the following therapeutic fields: Men's Health, Cardiovascular and Allergy / Respiratory.
- Atopiclair® Atopiclair® is a non-steroidal, clinically proven flare remission treatment for atopic dermatitis in adult and children over the age of 6 months.